Journal of Clinical Oncology, Vol 20, Issue 23
(December), 2002: 4559-4566
© 2002 American Society for Clinical Oncology
Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma
By Amnon Zisman,
Allan J. Pantuck,
Jeffery Wieder,
Debby H. Chao,
Fredrick Dorey,
Jonathan W. Said,
Jean B. deKernion,
Robert A. Figlin,
Arie S. Belldegrun
From the Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA.
Address reprint requests to Arie S. Belldegrun, MD, Department of Urology, University of California School of Medicine, 10833 Le Conte Ave, Rm 66-118 CHS, Los Angeles, CA 90095-1738; email: abelldegrun{at}mednet.ucla.edu
PURPOSE: To create a comprehensive algorithm that can predict postoperative renal cell carcinoma (RCC) patient outcomes and response to therapy.
PATIENTS AND METHODS: A prospective cohort study was performed with outcome assessment on the basis of chart review of 814 patients who underwent nephrectomy between 1989 and 2000. At diagnosis, M1 or N1/N2M0 metastatic disease (M) was present in 346 patients (43%), whereas 468 patients had no metastatic disease (NM) (N0M0). On the basis of UCLA Integrated Staging System category and the presence of metastases, patients were divided into low-risk (LR), intermediate-risk (IR), and high-risk (HR) groups. Decision boxes integrating tumor-node-metastasis staging, tumor grade, and performance status were compiled for determining a patient’s risk group.
RESULTS: NM-LR patients had 91% disease-specific survival at 5 years, lower recurrence rate, and better disease-free survival compared with NM-IR and HR patients. Disease progressed in 50% of NM-HR patients. Disease-specific survival of NM-HR patients who received immunotherapy (IMT) for recurrent disease was similar to that of M-LR patients treated with cytoreductive nephrectomy and adjuvant IMT. Time from recurrence to death for NM-HR patients was inferior to that for M-LR patients. After IMT, approximately 25% of M-LR and 12% of M-IR patients had long-term progression-free survival. M-HR patients did poorly despite IMT.
CONCLUSION: Stratifying RCC patients into high-, intermediate-, and low-risk subgroups provides a clinically useful system for predicting outcome and provides a unique tool for risk assignment and outcome analysis. Subclassifying RCC into well-defined risk groups should allow better patient counseling and identification of both NM-HR subgroups that need adjuvant treatment and nonresponders who need alternative therapies.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Klatte, D. B. Seligson, J. LaRochelle, B. Shuch, J. W. Said, S. B. Riggs, N. Zomorodian, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun
Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy
Cancer Epidemiol. Biomarkers Prev.,
March 1, 2009;
18(3):
894 - 900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Biswas, J. Kelly, and T. Eisen
Cytoreductive Nephrectomy in Metastatic Clear-Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era
Oncologist,
January 1, 2009;
14(1):
52 - 59.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mikami, M. Oya, M. Shimoda, R. Mizuno, M. Ishida, T. Kosaka, M. Mukai, M. Nakajima, and Y. Okada
Expression of Heparanase in Renal Cell Carcinomas: Implications for Tumor Invasion and Prognosis
Clin. Cancer Res.,
October 1, 2008;
14(19):
6055 - 6061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Vasudev, J. E. Brown, S. R. Brown, R. Rafiq, R. Morgan, P. M. Patel, D. O'Donnell, P. Harnden, M. Rogers, K. Cocks, et al.
Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival
Clin. Cancer Res.,
March 15, 2008;
14(6):
1775 - 1781.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Yao, C.-N. Qian, Z.-F. Zhang, M.-H. Tan, E. J. Kort, X. J. Yang, J. H. Resau, and B. T. Teh
Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications
Clin. Cancer Res.,
January 1, 2007;
13(1):
161 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin
Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma
J. Clin. Oncol.,
December 10, 2006;
24(35):
5565 - 5575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Eggener, O. Yossepowitch, J. A. Pettus, M. E. Snyder, R. J. Motzer, and P. Russo
Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence
J. Clin. Oncol.,
July 1, 2006;
24(19):
3101 - 3106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. Schuetz, Q. Yin-Goen, M. B. Amin, C. S. Moreno, C. Cohen, C. D. Hornsby, W. L. Yang, J. A. Petros, M. M. Issa, J. G. Pattaras, et al.
Molecular Classification of Renal Tumors by Gene Expression Profiling
J. Mol. Diagn.,
May 1, 2005;
7(2):
206 - 218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Lam, A. S. Belldegrun, and R. A. Figlin
Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy
Clin. Cancer Res.,
September 15, 2004;
10(18):
6304S - 6309S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Patard, H. L. Kim, J. S. Lam, F. J. Dorey, A. J. Pantuck, A. Zisman, V. Ficarra, K.-R. Han, L. Cindolo, A. De La Taille, et al.
Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study
J. Clin. Oncol.,
August 15, 2004;
22(16):
3316 - 3322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Pandha
Integrative Tumor Board: Metastatic Renal Cell Carcinoma
Integr Cancer Ther,
March 1, 2004;
3(1):
29 - 34.
[PDF]
|
|
|
|
